More News

15 April 2020

LEO Pharma Enters License Agreement with Oneness Biotech and Microbio Shanghai for FB825 a Novel Atopic Dermatitis and Asthma Drug Candidate

15 April 2020

TScan Announces Collaboration with Novartis on the Discovery and Development of Novel T Cell Receptor Therapies for the Treatment of Solid Tumors

14 April 2020

MEI Pharma and Kyowa Kirin Announce Global License, Development and Commercialization Agreement for ME-401

8 April 2020

Global COVID-19 Clinical Trial Tracker launched by Cytel

8 April 2020

Arrakis Therapeutics Enters Strategic Collaboration and License Agreement with Roche for Multi-Target Program Utilizing RNA-Targeted Small Molecule Drug Discovery Platform

7 April 2020

Beam Therapeutics Licenses SIRION Biotech’s LentiBOOST™ Technology for its CAR-T pipeline

6 April 2020

Gilead Sciences and Second Genome Announce Strategic Collaboration in Biomarker and Inflammatory Bowel Disease Drug Discovery

4 April 2020

Servier signed a definitive agreement to acquire Symphogen, a leading antibody discovery company, to boost its antibody capabilities and leverage its R&D pipeline

4 April 2020

panCELLa Extends Exclusive License to Astellas

2 April 2020

Kite Licenses Antibodies and Establishes Collaboration With Teneobio in Multiple Myeloma

2 April 2020

Horizon Therapeutics plc Acquires Curzion Pharmaceuticals, Inc. and Its LPAR1 Antagonist Product Candidate to Expand Development-Stage Pipeline

2 April 2020

Evotec Expands its iPSC-Based Cell Therapy Platform EVOcells Through Licensing Agreement with panCELLa

2 April 2020

AC Immune Presents the Latest Preclinical Data on Novel Drug Targets for Neurodegenerative Diseases

1 April 2020

Neurimmune and Ethris Sign Collaboration Agreement to Rapidly Develop Inhaled mRNA-based Antibody Therapy for the Treatment of COVID-19

1 April 2020

Daiichi Sankyo Enters into Strategic Partnership with Ultragenyx for Use of Gene Therapy Manufacturing Technology

1 April 2020

REGENXBIO and Ultragenyx Announce New License Agreement for Use of NAV® Technology Platform for the Treatment of Rare Metabolic Disorder

1 April 2020

Lilly and Sitryx Announce Licensing and Research Collaboration to Discover and Develop New Immunometabolic Medicines

27 March 2020

Ranok Therapeutics Announces Closing of Follow-on Seed Funding Round

27 March 2020

CG Oncology Announces License and Commercialization Agreement with Kissei Pharmaceutical Co., Ltd. for CG0070 in Japan and Other Asian Countries

26 March 2020

ReCode Therapeutics Raises $80 Million in Oversubscribed Series A Financing

26 March 2020

Evox Therapeutics and Takeda sign multi-target rare disease collaboration

26 March 2020

Saniona enters into second collaboration agreement with Boehringer Ingelheim in schizophrenia

26 March 2020

Laekna Acquires Exclusive Global Rights to Clinical-Stage Cancer Asset

26 March 2020

Forge Enters Into Collaboration With Roche To Develop Novel Antibiotic To Treat Lung Infections

26 March 2020

Debiopharm Expands Its Radiopharmaceutical Footprint with an Exclusive In-Licensing Agreement of 3B Pharmaceutical’s Targeted CAIX Radiotherapy

26 March 2020

Alector Enters into a Licensing Agreement with Innovent Biologics to Develop and Commercialize AL008 in Oncology Indications in China

25 March 2020

AstraZeneca to discover and develop siRNA therapeutics for Cardiovascular, Renal, Metabolic and Respiratory diseases in new collaboration

24 March 2020

CytomX Therapeutics and Astellas Announce Strategic Collaboration to Develop Probody® T-Cell Engaging Bispecific Therapies for Treatment of Cancer

24 March 2020

Pieris Pharmaceuticals Provides Update on Servier Collaboration

24 March 2020

Secarna Pharmaceuticals announces the acquisition of LNAplus based antisense drug candidates by Lipigon Pharmaceuticals

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Omalizumab (Xolair) Biosimilars & Biosuperiors Pipeline Review

Aflibercept (Eylea) Biosimilars Pipeline Review

2FOR1 Report Package: Vectorized Antibody and Prodrug Antibody & Cytokine landscape analysis report package with 50% discount

Adalimumab (Humira) Biosimilars Pipeline Review

Denosumab (Prolia & Xgeva) Biosimilars Pipeline Review

Masked Antibodies & Cytokines As Prodrugs: a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective

Report Package: “Drug the Undruggable” Technologies

Antibody Target, Technology & Pipeline Database: 1-Year Subscription

CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing

CD38-Targeted Antibody & Cell Therapy Pipeline Review